Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced Esophagogastric Adenocarcinoma
NCT02241720Phase 2Terminated
- Sponsor
- University of Utah
- Start
- May 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by University of Utah. Primary endpoint: Number of Participants With Stable Disease at Eight Weeks Post-Treatment at 8 weeks. Started May 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT02241720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241720.